



Cancer Disparity Research Partnership (CDRP) Program

Rosemary Wong, PhD

Program Director

ASTRO Program Expert Committee Meeting

November 1, 2010



CDRP Program Highlights

- **June 6, 2010 → Coastal Carolina Radiation Oncology (CCRO) receives ASCO 2010 Clinical Trials Participation Award**
- **June 18, 2010 → NOVA Research Co. submits Final U56 CDRP Evaluation Report to NCI**
- **June 30, 2010 → RRP sends CDRP PIs, EAC and Experts Final U56 CDRP Evaluation Report**
- **August 1, 2010 → U54 grantees issued year 2 awards**
- **Sept. 7, 2010 → NOVA Research Co. awarded 4-year U54 CDRP Evaluation contract**
- **Oct. 6, 2010 → RCRH partners with SD Dept. of Health to receive CDC grant for Patient Navigation project**

CDRP Program Reminders

- **Nov. 1, 2010 → ASTRO-NCI Diversity Symposium and Reception at 5:30PM at Aqua Room 313**
- **Nov. 30, 2010 → U56 Final Progress Report due to NCI from UPMC McKeesport, 21st Century Oncology and New Hanover Regional Medical Center**
- **Jan. 13-16, 2011 → NO CDRP PSC meeting at RTOG; may schedule a teleconference call in March 2011**
- **June 1, 2011 → U54 Annual Progress Report due to NCI**
- **June 16-19, 2011 → CDRP PSC meeting at RTOG in Philadelphia where PI present program update**

CDRP U56 Accomplishments – # Trials Open

TABLE 2 – NUMBER OF CLINICAL TRIALS OPEN PER FISCAL YEAR (AS OF SEPTEMBER 30, 2009)

Grantee Sites	Number of Clinical Trials Open per Fiscal Year (%)					
	FY04	FY05	FY06	FY07	FY08	FY09
Rapid City	48 (75)	52 (63)	76 (55)	98 (48)	101 (42)	94 (40)
Laredo	4 (6)	5 (6)	5 (4)	N/A	N/A	N/A
Centinela Freeman	0 (0)	5 (6)	6 (4)	3 (1)	6 ^a (2)	4 (2)
New Hanover	5 (8)	9 (11)	11 (8)	5 (2)	7 (3)	7 (3)
Singing River	0 (0)	1 (1)	20 (15)	40 (20)	39 (16)	61 (26)
UPMC McKeesport	7 (11)	10 (12)	19 (14)	57 (28)	89 (37)	69 (29)
Total^{b,c,d}	64 (100)	82 (100)	137 (100)	203 (100^e)	242 (100)	235 (100)

N/A = Not applicable; Laredo's CDRP grant was relinquished in 2007.

^a After closure of the radiation oncology center in January 2008, no new trials were open until August 2008 (see sections 3.3.2 and 3.7.2 for a description of events).

^b Trials opened in a given year that remained active (i.e., open to patient accrual) in subsequent years were counted each year they remained open.

^c Data do not include clinical trials that were opened for follow-up only.

^d Column percents do not total 100% due to rounding.

**2010
U54 Data****

89 - 91

4 - 6

12 - 14

50

48 - 52

206-211

**** 9 months
2010 data only**

Types of Clinical Trials Open by CDRP Site

TABLE 3 – TYPES OF CLINICAL TRIALS OPENED BY SITES (AS OF SEPTEMBER 30, 2009)

Grantee Sites	PI-Initiated	Mentor-Initiated	RTOG	Other Cooperative Groups ^a	Pharmaceutical/Industry	Total (%)
Rapid City	8	1	30	174 (2 R; 22 CR; 118 M/S; 32 CC/P)	1	214 (47)
Laredo	1	1	2	3 (2 CC/P; 1 UNK)	1	8 (2)
Centinela Freeman	0	0	5	1 (1 UNK)	2	8 (2)
New Hanover	1	1	9	7 (7 R/CR)	0	18 (4)
Singing River	0	0	20	63 (5 R/CR; 58 M/S ^b)	7	90 (20)
UPMC McKeesport	11 ^c	0	22	53 (1 R, 11 CR, 41 M/S)	28	114 (25)
Total	21¹³	3⁴	88⁴⁶	301¹³¹	39¹⁴	452 (100²⁰⁸)

^a Trial Category for Other Cooperative Groups: R = radiation only; CR = combined chemoradiation; M/S = medical and/or surgical; CC/P = cancer control and/or prevention; UNK = unknown category of trial.
^b Some medical/surgical oncology trials (n=15) opened at this site are also considered cancer control/prevention trials.
^c These patients are enrolled on UPMC PI-initiated trials via the University of Pittsburgh Cancer Institute (UPCI).
^d Column percents do not total 100% due to rounding.

**2010
U54 Data****

89 - 91

4 - 6

12 - 14

50

48 - 52

206-211

**** 9 months
2010 data only**

U56 Yearly Accrual by CT Types

TABLE 7 – CUMULATIVE NUMBER OF PATIENTS ACCRUED IN EACH TYPE OF CLINICAL TRIAL, BY FISCAL YEAR (AS OF SEPTEMBER 30, 2009)

‡

Type of Clinical Trial	FY03 ^a	FY04	FY05	FY06	FY07	FY08	FY09	Total (%)
PI-Initiated	0	1	44	78	78	38	62	301 (18)
Mentor-Initiated	0	0	0	0	0	0	160	160 (10)
RTOG	10	7	17	26	34	24	50	168 (10)
Other Cooperative Groups ^b	271	349	39	75	84	98	82	998 (60)
<i>Radiation Only</i>	1	0	4	20	9	0	3	37 (4)
<i>Radiation/Combined Treatment^c</i>	65	9	14	24	19	13	14	158 (16)
<i>Medical/Surgical^c</i>	140	25	24	27	55	79	57	407 (41)
<i>Cancer Control/Prevention^c</i>	75	316 ^c	6	9	10	11	14	441 (44)
Pharmaceutical/Industry	0	0	5	1	8	6	31	51 (3)
Total	281^a	357	105	180	204	166	385	1,678 (100^d)

^a Rapid City had approximately 33 active clinical protocols opened during FY03 in which they accrued 281 patients onto the STAR trial and cooperative group trials (RTOG and NCCTG) (n=281).

^b Rapid City data include patients who were enrolled onto both RTOG and other cooperative group trials. The database structure at this site did not allow segregating the different trial categories (e.g., radiation only, medical/surgical) by only cooperative group trials.

^c Includes Laredo's accruals to NCI prevention trials, STAR (n=9) and SABOR (300).

^d Column percents do not total 100% due to rounding.

**2010
U54 Data****

9

13

18

66

--

--

--

--

49

155

**** 9 months
2010 data only**

Accrual to Types of Clinical Trials

TABLE 6 – CUMULATIVE NUMBER OF PATIENTS ACCRUED AT EACH SITE BY TYPE OF CDRP CLINICAL TRIAL (AS OF SEPTEMBER 30, 2009)

Grantee Sites	PI-Initiated	Mentor-Initiated	RTOG	Other Cooperative Groups	Pharmaceutical / Industry	Total (%)
Rapid City	252	154	45	482	0	933 ^a (56)
Laredo	0	0	6	313 ^b	3	322 (19)
Centinela Freeman	0	0	17	16	30	63 ^c (4)
New Hanover	39	6	50	23	0	118 (7)
Singing River	0	0	18	106	6	130 ^d (8)
UPMC McKeesport	10 ^e	0	32	58	12	112 ^f (7)
Total	301	160	168	998	51	1,678^g (100%)

^aRapid City accrued 927 patients; 6 patients were on more than one clinical trial and were counted twice. Data includes CDRP prior accrual onto the STAR and cooperative group trials (RTOG and NCCTG) (n= 281).

^bIncludes accruals on prevention trials, STAR (n=9) and SABOR (n=300).

^cCentinela Freeman accrued 60 patients; 3 patients were on two different types of trials and were counted twice.

^dSinging River accrued 107 patients; about 20 patients were on two to four different types of clinical trials and were counted every time they participated in a trial.

^eThese patients were enrolled on UPMC PI-initiated trials via the University of Pittsburgh Cancer Institute (UPCI).

^fUPMC McKeesport accrued 110 patients, 2 patients were on two different types of trials and were counted twice.

^gThis total includes about 30 patients that were counted more than once because they participated in more than one clinical trial. The total number of unduplicated patients accrued was 1,644 (see Table 5).

^hColumn and row percents do not total 100% due to rounding.

**2010
U54 Data****

42

--

--

72

28

13

155

**** 9 months
2010 data only**

**18/155 = 11.6%
RTOG**

**66/155 = 42.6%
Coop. Group**

168/1678 = 10.0% RTOG accrual; 998/1678 = 59.5% Coop. Group accrual

Total Patients Accrued by Race

TABLE 5 – CUMULATIVE NUMBER OF PATIENTS ACCRUED TO CLINICAL TRIALS BY RACE/ETHNICITY FOR ALL SITES (AS OF SEPTEMBER 30, 2009)

Race/Ethnicity	Total Number of Patients Accrued to CDRP Clinical Trials (%)	
American Indian/Alaska Native	138	(8)
Asian	2	(0)
Native Hawaiian or Pacific Islander	1	(0)
Non-Hispanic Black or African American	100	(6)
Non-Hispanic White	1,071	(65)
Hispanic/Latino	331	(20)
Unknown	1	(0)
Total #	1,644^a	(100^b)

^a Includes patient accruals to clinical trials opened prior to CDRP: Laredo's accruals to SABOR (n=300) and STAR trials (n = 9) and Rapid City accruals to STAR and cooperative group trials (RTOG and NCCTG) (n=281).
^b Column percents do not total 100% due to rounding.

**2010
U54 Data****

2
1
0
17
130
0
0
150

**** 9 months
2010 data only**

**20/150 = 13.3% U54
minority accrual rate**

572/1644 = 34.8% U56 minority accrual rate

Eligibility Rates for Screened Pts

TABLE 8 - NUMBER OF PATIENTS SCREENED (SCR) AND ELIGIBLE (ELIG) FOR CANCER CLINICAL TRIALS, BY FISCAL YEAR (AS OF SEPTEMBER 30, 2009) *U54 Data – 9 months

Grantee Sites ^a	Patients Screened (FY07Q4 - FY09)	Patients Eligible (FY07Q4 - FY09)	Eligibility Rate ^b (%)
Rapid City	1,601 579	457 94	29 16
Centinela Freeman	28 0	28 0	100 ^c 0
New Hanover	228 256	84 116	37 45
Singing River	982 287	166 47	17 16
UPMC McKeesport	637 205	84 13	13 ^d 6
Total	3,476 1,327	819 270	24 20

^a Data were not available for Laredo.

^b Eligibility rate is based on the number of patients eligible divided by the number of patients screened.

^c Centinela Freeman did not screen all patients.

^d Only includes data on the UPMC McKeesport site out of a total of five participating hospital at this CDRP site.

Accrual Rates for Eligible Pts

TABLE 10 –PATIENT CLINICAL TRIAL ACCRUAL RATES BY SITE (AS OF SEPTEMBER 30, 2009)

Grantee Sites ^a	Eligible Patients (FY07Q4 - FY09)	Patients Accrued (FY07Q4 - FY09)	Patient Accrual Rate ^b (%)
Rapid City	457 94	343 42	75 45
Centinela Freeman	28 0	28 0	100 0
New Hanover	84 116	74 72	88 62
Singing River	166 47	87 23	52 49
UPMC McKeesport	84 13	68 3	81 ^c 23
Total	819 270	600 140	73 52

^a Data were not available for Laredo.

^b Accrual rate is based on the number of patients enrolled onto clinical trials divided by the number of patients eligible for clinical trials.

^c Only includes data on the UPMC McKeesport site out of five participating UPMC hospital sites.

U56 Planning Phase Findings

U56 Phase Identified:

- **Eligibility barriers:** shortage of trials, restrictive enrollment criteria; co-morbidities; advanced stage of disease; etc.
- **Accrual barriers:** insurance, performance status, age, transportation standard treatment preference; etc.

Therefore, new strategies and disparity appropriate protocols must be designed for minority/underserved populations

U56 Planning Phase (2002 - 2009)


- Establish clinical research infrastructure at community hospitals
- Create community educational and outreach program
- Establish individual patient navigation program to address minority and underserved population needs
- Use Telesynergy® to facilitate mentoring, training and collaborations
- Increase presentations and publications on various aspects and components of CDRP program
- CDRP heightened awareness of cancer disparities in RTOG and establish annual NCI ASTRO Diversity Symposium

U54 Implementation Phase (2009 - 2013)


- Limited Competition RFA issued October 2008
- Five applications rec'd 12/08, reviewed 3/09
- Awards made August/September 2009

Goals:

- Expand minority/underserved patient accrual into all types of NCI clinical trials
- Develop strategies to address U56 identified barriers to accrual
- Disseminate best practices via publications and presentations at national meetings
- Continue efforts toward future program sustainability by securing non-NIH funding



CDRP grantees will require new home after pilot program ends in 2013



Updated Radiation Research Program Website

(<http://rrp.cancer.gov>)

Radiation Research Program (RRP)

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

RRP Radiation Research Program

DCTD
Division of Cancer
Treatment and Diagnosis

Home Research Funding Programs & Resources Clinical Trials Reports & Publications Education Research Links About RRP

Radiation Research Program (RRP)

Welcome to the Radiation Research Program

The RRP is responsible for NCI's clinically-related extramural radiation research program. The RRP establishes priorities, allocates resources, and evaluates the effectiveness of such radiation research being conducted by NCI grantees. RRP staff represent the program at NCI management and scientific meetings and provide scientific support to leadership on matters related to radiation research. The RRP coordinates its activities with other radiation research programs at NCI, NIH, other Federal agencies, and national and international research organizations, and it provides a focal point within NIH for extramural investigators concerned with clinically related radiation research.

RRP is divided into three branches: The Radiotherapy Development Branch (RDB), the Clinical Radiation Oncology Branch (CROB) and the Molecular Radiation Therapeutics Branch (MRTB).

As part of ongoing efforts to stimulate research in radiotherapy and radiation biology, the RRP supports basic, translational, and clinical research at the Division of Cancer Treatment and Diagnosis (DCTD) by:

ASSOCIATE DIRECTOR

 C. Norman Coleman, MD, Associate Director for the Radiation Research Program (RRP), received his medical training at the Yale University School of Medicine. Dr. Coleman completed his internship and residency in internal medicine at the University of California, San Francisco, a fellowship in medical oncology at NCI, and a fellowship in radiation oncology at Stanford University. He is board-certified in internal medicine, medical oncology, and radiation oncology.

Dr. Coleman was a tenured faculty member in Radiology and Medicine at the Stanford University School of Medicine before joining Harvard Medical School in 1985 as the Alvan T. and Viola D. Fuller-American Cancer Society Professor and Chairman of the Joint Center for

CDRP Website Within RRP Website

<http://rrp.cancer.gov/initiatives/cdrp/index.htm>

The screenshot shows a web browser window displaying the Cancer Disparities Research Partnership (CDRP) Program website. The browser's address bar shows the URL <http://rrp.cancer.gov/initiatives/cdrp/index.htm>. The page features a red header with the National Cancer Institute logo and name, and the U.S. National Institutes of Health logo and website address. Below the header is a blue banner with the CDRP logo and the text "CANCER DISPARITIES RESEARCH PARTNERSHIP PROGRAM".

The main content area is divided into several sections:

- Left Sidebar:** A vertical menu with links to Home, About CDRP, Cooperative Planning Grant, Clinical Trials, TELESYNERGY®, Patient Navigator Program, Resources, Contact Us, and Radiation Research Program. Below these links is contact information for the Radiation Research Program: National Cancer Institute, 6130 Executive Boulevard, Suite 6000, Rockville, MD 20892.
- About CDRP:** A section with the heading "About CDRP" and a list of links: [Background](#), [The Challenge Ahead](#), and [Health Disparities in Cancer](#).
- Image Grid:** A 3x3 grid of nine small portrait photographs of diverse individuals.
- Cooperative Planning Grant for Cancer Disparities Research Partnership (CDRP) Program:** A section with the heading "Cooperative Planning Grant for Cancer Disparities Research Partnership (CDRP) Program" and a list of links: [Objective and Scope](#), [U54 and U56 Award Mechanism](#), [Target Populations](#), [Funded Institutions](#), [Funded Institution's Program Presentations](#), and [CDRP Symposium Presentations](#).
- Image:** A photograph of two hands, one larger and one smaller, clasped together, symbolizing support and partnership.

The browser's status bar at the bottom shows "Done".